0001209191-20-064574.txt : 20201218
0001209191-20-064574.hdr.sgml : 20201218
20201218202901
ACCESSION NUMBER: 0001209191-20-064574
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201216
FILED AS OF DATE: 20201218
DATE AS OF CHANGE: 20201218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zinda Michael
CENTRAL INDEX KEY: 0001815366
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39335
FILM NUMBER: 201402107
MAIL ADDRESS:
STREET 1: C/O REPARE THERAPEUTICS INC.
STREET 2: 7210 FREDERICK-BANTING, SUITE 100
CITY: ST-LAURENT
STATE: A8
ZIP: H4S 2A1
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Repare Therapeutics Inc.
CENTRAL INDEX KEY: 0001808158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7210 FREDERICK-BANTING, SUITE 100
CITY: ST-LAURENT
STATE: A8
ZIP: H4S 2A1
BUSINESS PHONE: (857) 412-7018
MAIL ADDRESS:
STREET 1: 7210 FREDERICK-BANTING, SUITE 100
CITY: ST-LAURENT
STATE: A8
ZIP: H4S 2A1
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-16
0
0001808158
Repare Therapeutics Inc.
RPTX
0001815366
Zinda Michael
C/O REPARE THERAPEUTICS INC.
7210 FREDERICK-BANTING, SUITE 100
ST-LAURENT
A8
H4S 2A1
QUEBEC, CANADA
0
1
0
0
EVP, Chief Science Officer
Common Stock
2020-12-16
4
M
0
6876
1.637
A
92105
D
Common Stock
2020-12-16
4
M
0
2080
1.637
A
94185
D
Common Stock
2020-12-16
4
S
0
8022
35.17
D
86163
D
Common Stock
2020-12-16
4
S
0
934
36.01
D
85229
D
Common Stock
2020-12-18
4
M
0
8321
2.062
A
93550
D
Common Stock
2020-12-18
4
S
0
8121
34.59
D
85429
D
Common Stock
2020-12-18
4
S
0
200
35.10
D
85229
D
Employee Stock Option (right to buy)
1.637
2020-12-16
4
M
0
6876
0.00
D
2027-06-14
Common Stock
6876
4122
D
Employee Stock Option (right to buy)
1.637
2020-12-16
4
M
0
2080
0.00
D
2027-12-04
Common Stock
2080
29538
D
Employee Stock Option (right to buy)
2.062
2020-12-18
4
M
0
8321
0.00
D
2029-03-29
Common Stock
8321
85707
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to
$35.753 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in
footnotes (1), (2), (3) and (4).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.23 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.99 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.05 to $35.15 inclusive.
Twenty-five percent (25%) of the shares subject to the option vested on June 14, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
Twenty-five percent (25%) of the shares subject to the option vested on June 22, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
Twenty-five percent (25%) of the shares subject to the option vested on March 29, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
/s/ Steve Forte, Attorney-in-Fact
2020-12-18